Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Current Assets (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Current Assets for 7 consecutive years, with $312.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets fell 38.84% to $312.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $312.4 million, a 38.84% decrease, with the full-year FY2024 number at $434.9 million, up 46.65% from a year prior.
  • Current Assets was $312.4 million for Q3 2025 at 4D Molecular Therapeutics, up from $303.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $552.6 million in Q2 2024 to a low of $165.7 million in Q3 2021.
  • A 5-year average of $316.3 million and a median of $296.6 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: surged 158.69% in 2024, then crashed 45.12% in 2025.
  • 4D Molecular Therapeutics' Current Assets stood at $256.3 million in 2021, then fell by 13.96% to $220.5 million in 2022, then skyrocketed by 34.5% to $296.6 million in 2023, then skyrocketed by 46.65% to $434.9 million in 2024, then fell by 28.18% to $312.4 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Current Assets are $312.4 million (Q3 2025), $303.3 million (Q2 2025), and $332.6 million (Q1 2025).